NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Sino Biological's Nipah Virus Research Reagent Expansion
TL;DR
Sino Biological's accelerated development of Nipah virus research tools provides researchers with a critical advantage in the race to develop vaccines and treatments for this high-mortality pathogen.
Sino Biological is producing high-purity NiV G and F proteins, along with N proteins and F trimers, to support research into viral entry mechanisms and therapeutic antibody screening.
By providing essential research tools for Nipah virus, Sino Biological helps accelerate global efforts to develop life-saving vaccines and diagnostics, potentially reducing future outbreaks and fatalities.
Nipah virus has a 40-75% fatality rate, and Sino Biological's new research reagents target its proteins to help scientists understand and combat this dangerous pathogen.
Found this article helpful?
Share it with your network and spread the knowledge!
Sino Biological is expanding and accelerating the availability of research reagents for Nipah virus (NiV) to support global scientific efforts in developing vaccines and diagnostics.
Nipah virus is classified by WHO as a priority pathogen due to its epidemic potential and high fatality rate (40-75%), with recent infections in West Bengal, India reigniting global concern and no approved vaccines or specific antiviral treatments currently available.
Sino Biological has launched high-purity NiV G and F proteins, is fast-tracking development of NiV N proteins and pre-fusion/post-fusion F trimer proteins, and offers ProPure™ endotoxin-free versions of NiV G and F proteins for vaccine research.
The new NiV N proteins are based on the most recently reported strains, offering improved sequence relevance compared with existing products that contain multiple mutations.
The ProPure™ endotoxin-free versions of NiV G and F proteins are specifically designed for vaccine research applications where immunogen purity and endotoxin control are critical.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, stated that their mission is to provide high-quality tools rapidly when emerging infectious diseases threaten global health.
Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services, serving researchers in over 90 countries and supporting basic research, drug discovery, vaccine development, and diagnostics.
This announcement was made on January 28, 2026, in response to recent reports of Nipah virus infections in West Bengal, India.
Researchers can visit Sino Biological's website at www.sinobiological.com or specifically https://www.sinobiological.com/research/virus/nipah-virus and https://www.sinobiological.com/research/virus/niv-proteins-reagent.
For media inquiries or partnership opportunities, contact Sino Biological, Inc. at gmo@sinobiological.cn.
Curated from NewMediaWire
